SOCS2 and hepatocellular carcinoma: One study suggested that silencing of METTL3 in HepG2 cells was strongly associated with a noteworthy enhancement of the p53 signalling pathway.6 In addition, it was observed that METTL3 was drastically up‐regulated in HCC patients, with a positive correlation with the higher grade of HCC.87 Tumour suppressor SOCS2 was observed to be the direct downstream target of METTL3.